5-alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.

Randomized clinical trials have shown that use of 5α-reductase inhibitors (5-ARIs) lowers overall prostate cancer (PCa) risk compared to placebo, while the proportion of Gleason 8-10 tumors is elevated.

It is unknown whether this affects PCa-specific survival. We studied disease-specific survival by 5-ARI usage in a cohort of 6,537 prostate cancer cases diagnosed in the Finnish Prostate Cancer Screening Trial and linked to the national prescription database for information on medication use. Cox proportional hazards regression was used to estimate hazard ratios and 95% confidence intervals for prostate cancer-specific deaths. For comparison, survival among alpha-blocker users was also evaluated. During the median follow-up of 7. 5 years after diagnosis a total of 2,478 men died; 617 due to prostate cancer and 1,861 due to other causes. The risk of prostate cancer death did not differ between 5-ARI users and non-users (multivariable adjusted HR 0. 94, 95% CI 0. 72-1. 24 and HR 0. 98, 95% CI 0. 69-1. 41 for usage before and after the diagnosis, respectively). Alpha-blocker usage both before and after diagnosis was associated with increased risk of prostate cancer death (HR 1. 29, 95% CI 1. 08-1. 54 and HR 1. 56, 95% CI 1. 30-1. 86, respectively). The risk increase vanished in long-term alpha-blocker usage. Use of 5-ARIs does not appear to affect prostate cancer mortality when used in management of benign prostatic hyperplasia. Increased risk associated with alpha-blocker usage should prompt further exploration on the prognostic role of lower urinary tract symptoms. This article is protected by copyright. All rights reserved.

International journal of cancer. Journal international du cancer. 2016 Jan 25 [Epub ahead of print]

Teemu J Murtola, Elina K Karppa, Kimmo Taari, Kirsi Talala, Teuvo Lj Tammela, Anssi Auvinen

University of Tampere, School of Medicine, Tampere, Finland. , University of Tampere, School of Medicine, Tampere, Finland. , Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. , Finnish Cancer Registry, Helsinki, Finland. , University of Tampere, School of Medicine, Tampere, Finland. , University of Tampere, School of Health Sciences, Tampere, Finland.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe